Structure-function studies of sponge-derived compounds on the cardiac CaV3.1 channel
Depuydt, A.-S.; Patel, P.A.; Toplak, Ž.; Bhat, C.; Vorácová, M.; Eteläinen, I.; Vitulano, F.; Bruun, T.; Lempinen, A.; Hribernik, N.; Mäki-Lohiluoma, E.; Hendrickx, L.; Pinheiro-Junior, E.L.; Tomašic, T.; Mašic, L.P.; Yli-Kauhaluoma, J.; Kiuru, P.; Tytgat, J.; Peigneur, S. (2023). Structure-function studies of sponge-derived compounds on the cardiac CaV3.1 channel. International Journal of Molecular Sciences 24(4): 3429. https://dx.doi.org/10.3390/ijms24043429 In: International Journal of Molecular Sciences. MDPI AG: Basel. ISSN 1661-6596; e-ISSN 1422-0067, more |   |
| Keyword | | | Author keywords | T-type calcium channels; ion channels; purpurealidin I; bromotyrosines; marine-derived bioactive compounds |
| Authors | | Top | - Depuydt, A.-S., more
- Patel, P.A.
- Toplak, Ž.
- Bhat, C.
- Vorácová, M.
- Eteläinen, I.
- Vitulano, F.
| - Bruun, T.
- Lempinen, A.
- Hribernik, N.
- Mäki-Lohiluoma, E.
- Hendrickx, L., more
- Pinheiro-Junior, E.L., more
| - Tomašic, T.
- Mašic, L.P.
- Yli-Kauhaluoma, J.
- Kiuru, P.
- Tytgat, J., more
- Peigneur, S., more
|
| Abstract | T-type calcium (CaV3) channels are involved in cardiac automaticity, development, and excitation–contraction coupling in normal cardiac myocytes. Their functional role becomes more pronounced in the process of pathological cardiac hypertrophy and heart failure. Currently, no CaV3 channel inhibitors are used in clinical settings. To identify novel T-type calcium channel ligands, purpurealidin analogs were electrophysiologically investigated. These compounds are alkaloids produced as secondary metabolites by marine sponges, and they exhibit a broad range of biological activities. In this study, we identified the inhibitory effect of purpurealidin I (1) on the rat CaV3.1 channel and conducted structure–activity relationship studies by characterizing the interaction of 119 purpurealidin analogs. Next, the mechanism of action of the four most potent analogs was investigated. Analogs 74, 76, 79, and 99 showed a potent inhibition on the CaV3.1 channel with IC50’s at approximately 3 μM. No shift of the activation curve could be observed, suggesting that these compounds act like a pore blocker obstructing the ion flow by binding in the pore region of the CaV3.1 channel. A selectivity screening showed that these analogs are also active on hERG channels. Collectively, a new class of CaV3 channel inhibitors has been discovered and the structure–function studies provide new insights into the synthetic design of drugs and the mechanism of interaction with T-type CaV channels. |
|
